Data from full set of subjects was statistically significant for the primary efficacy endpoint (p
Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting
Trevi Therapeutics, Inc. on 6ix
Story so far
- Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
- Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release
Earlier from Trevi Therapeutics
- Trevi Therapeutics Announces Proposed Public Offering
- Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
- Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022
- Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release
Later from Trevi Therapeutics
- Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022
- Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
- Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
- Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer
- Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference
Follow Trevi Therapeutics into a list and get an email when it puts out news.
Follow Trevi Therapeutics